 education. The key takeaway from today's event really is the fact is that the patients have a lot of options for therapies and therapies that we never had years ago. I think surgery is still the most important interaction that people should have with their surgeon in regards to taking out the tumor ideally. If not, they don't target therapies and immunotherapies which have been becoming the standard of care over the last several years. Immunotherapy still is I think the prime therapy one should always consider at the start of their treatment options. But now we're seeing that these more immunotherapies coming over the course of the next few years that will have a lot more information and therapy to benefit for our patients. In the mean time the target therapy seems to be very beneficial. I think the target therapies have gotten the patients the opportunity to be on their treatments for seven years. Given that quality of life as well as life itself has improved survival. And sometimes the physicians need to adjust their peace around the patients achieving the goal of not only survival but quality of life. These meetings today I think are amazing. I think for patients to be able to be informed of the options that they have. They can identify a little bit in regards to what they've had experiences with and what their future may be. It gives them the chance to make them part of them being their own advocate. They can definitely hear what people are saying about them. They'll be part of their coach about how therapies can be more beneficial for their own treatments. And it gives them a sense that the future has a lot of information and applicability to them that they can actually benefit from and not only hear and better today but be part of this medical trials in the future.